A team of Chinese researchers has developed an autonomous robotic system capable of performing delicate eye injections within ...
A team of Chinese researchers has developed an autonomous robotic system that is capable of performing delicate eye ...
According to a recent groundbreaking study published in the journal Science Robotics by Chinese researchers, a new autonomous ...
Chinese researchers have developed an autonomous robotic system capable of performing highly delicate eye injections inside the confined space of the ...
Chinese researchers have developed an autonomous robotic system capable of performing delicate eye injections with ...
DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...
Chinese researchers have developed an autonomous robotic system capable of performing highly delicate eye injections within the confined space of the human eye, a breakthrough that could significantly ...
Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028 DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene ...
A team of Chinese researchers has developed an autonomous robotic system that is capable of performing delicate eye ...
In both the Phase 1 and Phase 2 clinical trials no OCU410-related serious adverse events were observed and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ...
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results